News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,438 Results
Type
Article (42501)
Company Profile (294)
Press Release (675643)
Multimedia
Podcasts (80)
Webinars (12)
Section
Business (210452)
Career Advice (2091)
Deals (36632)
Drug Delivery (107)
Drug Development (83062)
Employer Resources (175)
FDA (16578)
Job Trends (15410)
News (356072)
Policy (33924)
Tag
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (90)
Alliances (51438)
ALS (92)
Alzheimer's disease (1397)
Antibody-drug conjugate (ADC) (132)
Approvals (16582)
Artificial intelligence (268)
Autoimmune disease (23)
Automation (16)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (111)
Biotechnology (188)
Bladder cancer (77)
Brain cancer (29)
Breast cancer (281)
Cancer (2290)
Cardiovascular disease (182)
Career advice (1752)
Career pathing (31)
CAR-T (152)
Cell therapy (429)
Cervical cancer (19)
Clinical research (67535)
Collaboration (855)
Compensation (530)
Complete response letters (25)
COVID-19 (2661)
CRISPR (46)
C-suite (248)
Cystic fibrosis (103)
Data (2211)
Decentralized trials (2)
Denatured (28)
Depression (45)
Diabetes (274)
Diagnostics (6452)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (111)
Drug shortages (28)
Duchenne muscular dystrophy (94)
Earnings (88292)
Editorial (38)
Employer branding (21)
Employer resources (149)
Events (115254)
Executive appointments (738)
FDA (17846)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (757)
Gene editing (111)
Generative AI (21)
Gene therapy (318)
GLP-1 (748)
Government (4538)
Grass and pollen (5)
Guidances (59)
Healthcare (18998)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (30)
Infectious disease (2804)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (322)
IPO (16785)
IRA (47)
Job creations (4057)
Job search strategy (1492)
Kidney cancer (10)
Labor market (38)
Layoffs (491)
Leadership (18)
Legal (8379)
Liver cancer (76)
Lung cancer (322)
Lymphoma (155)
Machine learning (7)
Management (59)
Manufacturing (318)
MASH (68)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (20386)
Metabolic disorders (706)
Multiple sclerosis (80)
NASH (17)
Neurodegenerative disease (94)
Neuropsychiatric disorders (29)
Neuroscience (1952)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Now hiring (39)
Obesity (377)
Opinion (231)
Ovarian cancer (76)
Pain (95)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (239)
Patient recruitment (111)
Peanut (49)
People (59274)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20946)
Phase II (29713)
Phase III (22270)
Pipeline (1197)
Policy (151)
Postmarket research (2654)
Preclinical (8925)
Press Release (68)
Prostate cancer (107)
Psychedelics (31)
Radiopharmaceuticals (251)
Rare diseases (398)
Real estate (6258)
Recruiting (67)
Regulatory (23139)
Reports (46)
Research institute (2370)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (132)
Series B (85)
Service/supplier (12)
Sickle cell disease (55)
Special edition (15)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3726)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (43)
The Weekly (50)
Vaccines (706)
Venture capitalists (41)
Weight loss (253)
Women's health (35)
Worklife (16)
Date
Today (163)
Last 7 days (860)
Last 30 days (2665)
Last 365 days (33359)
2025 (10765)
2024 (35772)
2023 (40634)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35771)
2017 (33142)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (53)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (40725)
Australia (6521)
California (6137)
Canada (2020)
China (537)
Colorado (268)
Connecticut (273)
Delaware (149)
Europe (86941)
Florida (910)
Georgia (205)
Idaho (57)
Illinois (546)
India (26)
Indiana (315)
Iowa (11)
Japan (165)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (895)
Massachusetts (4616)
Michigan (221)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1737)
New Mexico (29)
New York (1746)
North Carolina (984)
North Dakota (8)
Northern California (2677)
Ohio (203)
Oklahoma (14)
Oregon (39)
Pennsylvania (1382)
Puerto Rico (12)
Rhode Island (33)
South America (1162)
South Carolina (22)
South Dakota (1)
Southern California (2300)
Tennessee (101)
Texas (913)
United States (23254)
Utah (182)
Virginia (153)
Washington D.C. (61)
Washington State (558)
West Virginia (3)
Wisconsin (56)
718,438 Results for "ionis pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren
Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide catch up?
March 17, 2025
·
3 min read
·
Jia Jie Chen
Collaboration
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge of late-stage development as well as regulatory and commercialization activities.
March 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Ionis reports first quarter 2025 financial results
April 30, 2025
·
16 min read
Press Releases
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
March 27, 2025
·
7 min read
Press Releases
Ionis to host expert panel discussion on sHTG
April 3, 2025
·
1 min read
Press Releases
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
March 12, 2025
·
3 min read
Press Releases
Ionis to hold first quarter 2025 financial results webcast
April 16, 2025
·
1 min read
Press Releases
Ionis to present at upcoming investor conferences - March 31, 2025
April 1, 2025
·
1 min read
Press Releases
Ionis to present at upcoming March 2025 investor conferences
February 26, 2025
·
1 min read
Press Releases
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
March 12, 2025
·
5 min read
1 of 71,844
Next
